News

Teva news, press releases, and media contact information

Press Releases
Keyword Search
 
  
For all global news, visit our corporate site.
05/15/2018Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical AssociationJERUSALEM--(BUSINESS WIRE)--May 15, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of ... 
05/03/2018Teva Reports First Quarter 2018 Financial ResultsRevenues of $5.1 billion Free cash flow of $1.9 billion GAAP EPS of $1.03 N... 
05/02/2018Teva to Present AUSTEDO® (deutetrabenazine) Tablets Data at the American Psychiatric Association 2018 Annual MeetingThree abstracts evaluate the long-term safety and efficacy of AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesi... 
04/27/2018Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mLUp to 7-year efficacy, safety and tolerability results from the GALA open-label extension study presented at the 70th Annual Meeting of ... 
04/23/2018Teva to Report First Quarter 2018 Financial Results on May 3, 2018JERUSALEM--(BUSINESS WIRE)--Apr. 23, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fi... 
04/17/2018Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of NeurologyTwo platform presentations and 19 posters explore the potential of fremanezumab as an investigational treatment option for the prevention ... 
03/26/2018Teva Announces the Launch of a Generic Version of Lialda® in the United StatesJERUSALEM--(BUSINESS WIRE)--Mar. 26, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a g... 
03/23/2018Teva Announces the Launch of a Generic Version of ALOXI® in the United StatesJERUSALEM--(BUSINESS WIRE)--Mar. 23, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the launch of a generic ve... 
03/12/2018Teva to Present at the Cowen & Company 38th Annual Healthcare ConferenceJERUSALEM--(BUSINESS WIRE)--Mar. 12, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at ... 
02/21/2018Teva Announces New Brand Positioning and Visual Identity in North AmericaTeva Pharmaceutical is announcing a new brand positioning and visual identity in North America. The new brand will continue to roll out globally throu... 
02/20/2018Teva Announces Exclusive Launch of Two Strengths of a Generic Version of Solodyn® in the United StatesJERUSALEM--(BUSINESS WIRE)--Feb. 20, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive lau... 
02/12/2018Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation AerosolFirst and Only Breath-Actuated Aerosol Inhaled Corticosteroid in the United States Designed to Help Eliminate the Need for Hand-Breath C... 
02/09/2018Teva Announces Launch of a Generic Version of Syprine® in the United StatesJERUSALEM--(BUSINESS WIRE)--Feb. 9, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of gene... 
02/08/2018Teva Reports 2017 Full Year and Fourth Quarter Financial ResultsJERUSALEM--(BUSINESS WIRE)--Feb. 8, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the year and the q... 
01/25/2018Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results at 8 a.m. ET on February 8, 2018JERUSALEM--(BUSINESS WIRE)--Jan. 25, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will issue a press ... 
01/15/2018Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic LeukemiaJERUSALEM--(BUSINESS WIRE)--Jan. 15, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and D... 
01/08/2018Teva Announces Global License Agreement with Alder BioPharmaceuticals® in the Field of Anti-CGRP-Based TherapyJERUSALEM--(BUSINESS WIRE)--Jan. 8, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that its subsidiary... 
01/04/2018Teva to Present at the 36th Annual J.P. Morgan Healthcare ConferenceJERUSALEM--(BUSINESS WIRE)--Jan. 4, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 36th A... 
01/02/2018Teva Announces Launch of an Authorized Generic of Estrace® Cream in the United StatesJERUSALEM--(BUSINESS WIRE)--Jan. 2, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an a...